Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF INFORMATION ABOUT REPORTED SEGMENT PROFIT OR LOSS AND ASSETS (Details)

v3.22.2.2
SCHEDULE OF INFORMATION ABOUT REPORTED SEGMENT PROFIT OR LOSS AND ASSETS (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting Information [Line Items]        
Revenues $ 1,914 $ 1,010 $ 6,292 $ 7,773
Operating gain (loss)     (7,930) (5,688)
Financing expenses, net     (11,735) (17,360)
Other losses (396)
Share in losses of affiliated companies accounted for under equity method, net     60 (1,499)
Net loss $ (5,630) $ (10,379) (20,001) (24,547)
Breast Cancer Test [Member]        
Segment Reporting Information [Line Items]        
Revenues    
Operating gain (loss)     (1,352) (4,685)
Net loss     (1,352) (4,685)
Alzheimer [Member]        
Segment Reporting Information [Line Items]        
Revenues    
Operating gain (loss)    
Net loss    
COVID-19 Testing [Member]        
Segment Reporting Information [Line Items]        
Revenues     6,292 7,773
Operating gain (loss)     1,061 (1,003)
Net loss     1,061 (1,003)
Unallocated [Member]        
Segment Reporting Information [Line Items]        
Revenues    
Operating gain (loss)     (7,639)
Financing expenses, net     (11,735) (17,360)
Other losses     (396)  
Share in losses of affiliated companies accounted for under equity method, net     60 (1,499)
Net loss     $ (19,710) $ (18,859)